Evaluating the Benefit of Concurrent Tricuspid Valve Repair During Mitral Surgery
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02675244 |
|
Recruitment Status :
Active, not recruiting
First Posted : February 5, 2016
Last Update Posted : November 9, 2022
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
The purpose of the research is to determine whether repairing a tricuspid valve (TV) in patients with mild to moderate tricuspid regurgitation (TR), at the time of planned mitral valve surgery (MVS), would improve the heart health of those who receive it compared to those who do not.
At this point, the medical community is split in their opinion on whether surgeons should routinely repair mild to moderate TR in patients who are undergoing planned mitral valve surgery, and this study will answer this question.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Mild Tricuspid Regurgitation Moderate Tricuspid Regurgitation Tricuspid Regurgitation | Procedure: TV Annuloplasty Procedure: MVS | Not Applicable |
The tricuspid valve controls the flow of blood in your heart between the right ventricle and the right atrium. TR is a condition where the valve does not close fully when it is supposed to and blood can then leak back into the right atrium. When TR becomes severe, surgery is usually performed to correct it. The purpose of the research is to determine whether repairing a tricuspid valve in patients with mild to moderate TR, at the time of planned mitral valve surgery, would improve the heart health of those who receive it compared to those who do not. There are no new or "experimental" procedures being tested in this study: both the mitral valve procedure and the tricuspid valve repair procedure are well established surgeries and are regularly performed together in patients who have severe TR. The available evidence addressing this issue is not definite: it is based on less rigorous methods of investigation, and the results have been conflicting. The study being proposed here will use rigorous scientific methods and should result in a very high level of certainty about what surgical treatment is best for patients with your condition.
This study will enroll people scheduled for mitral valve surgery with mild to moderate tricuspid regurgitation.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 401 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | Evaluating the Benefit of Concurrent Tricuspid Valve Repair During Mitral Surgery |
| Actual Study Start Date : | May 26, 2016 |
| Actual Primary Completion Date : | April 19, 2021 |
| Estimated Study Completion Date : | April 19, 2024 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: MVS Alone
Participants will undergo mitral valve surgery alone.
|
Procedure: MVS
MVS will be performed using standard surgical techniques |
|
Active Comparator: MVS + TV Annuloplasty
Patients will undergo mitral valve surgery and tricuspid valve annuloplasty.
|
Procedure: TV Annuloplasty
TV Annuloplasty will be performed using standard surgical techniques Procedure: MVS MVS will be performed using standard surgical techniques |
- Degree of TR Repair [ Time Frame: 24 Months ]Effectiveness of TR Repair assessed by a composite of death, reoperation for TR, or progression of TR from baseline by two grades or the presence of severe TR at 24 months.
- MACCE [ Time Frame: up to 24 Months ]Major Adverse Cardiac and Cerebrovascular Events (MACCE) is defined as a non-weighted composite score comprised of the following components: Death, Stroke, and Serious heart failure events
- NYHA Classification [ Time Frame: up to 24 Months ]Functional status will be assessed by the New York Heart Association (NYHA) Classification scale which ranges from 1 (no physical limitations) to 4 (severe limitation of physical activity).
- Diuretic Use [ Time Frame: up to 24 Months ]The diuretic requirements of patients will be assessed.
- Six Minute Walk Test [ Time Frame: up to 24 Months ]The total distance walked in six minutes will be assessed.
- Degree of TR [ Time Frame: up to 24 Months ]Degree of TR assessed by echocardiography, categorized according to American Society of Echocardiography guidelines as none/mild/moderate/severe.
- Right Ventricular size [ Time Frame: up to 24 Months ]Right ventricular (RV) size assessed by echocardiography.
- Degree of RV function [ Time Frame: up to 24 Months ]Degree of RV function assessed by echocardiography as normal, mildly impaired, moderately impaired, severely impaired.
- Peak tricuspid annular velocity [ Time Frame: up to 24 Months ]Degree of RV function assessed by peak tricuspid annular velocity
- Tricuspid annular peak systolic excursion (TAPSE) [ Time Frame: up to 24 Months ]Degree of RV function assessed by TAPSE
- Right ventricular fractional area change (RVFAC) [ Time Frame: up to 24 Months ]Degree of RV function assessed by RVFAC
- Pulmonary Artery Pressure [ Time Frame: up to 24 Months ]Pulmonary artery pressure assessed by echocardiography.
- Right Ventricular Volume [ Time Frame: up to 24 Months ]RV Volume as measured by transthoracic 3D echocardiography.
- SF-12 [ Time Frame: up to 24 Months ]Quality of Life assessed by SF-12. A measure of perceived health (health-related quality of life [QoL]) that describes the degree of general physical health status and mental health distress. Higher scores indicate higher levels of health.
- Kansas City Cardiomyopathy Questionnaire (KCCQ) [ Time Frame: up to 24 Months ]Quality of Life assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ). KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life, in which higher scores reflect better health status.
- EuroQoL (EQ-5D) [ Time Frame: up to 24 Months ]Quality of Life assessed by EuroQoL (EQ-5D) - a standardised instrument for use as a measure of health outcome. Higher scores indicate higher levels of health.
- Survival [ Time Frame: up to 60 Months ]Incidence of participants alive
- Length of Index Hospitalization [ Time Frame: average 30 days ]
- Readmission [ Time Frame: up to 24 months ]Incidence of readmissions
- Reoperations [ Time Frame: up to 24 months ]Incidence of reoperations
- Economic Measures (Inpatient costs) [ Time Frame: up to 60 months ]Inpatient costs will be measured through the collection of hospital billing.
- Serious adverse events [ Time Frame: 60 months ]Safety as measured by frequency of serious adverse events.
- Gait Speed Test [ Time Frame: up to 24 months ]Frailty will be assessed using the Gait Speed Test, which measures the speed of three 5 meter walks
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Undergoing MVS for degenerative MR* with (a) Moderate TR as determined by transthoracic 2D echocardiography, or (b) Tricuspid annular dimension ≥ 40 mm (index: ≥21mm/M2 BSA) and none/trace or mild TR, determined by echocardiography.
- Age ≥ 18 years
-
Able to sign Informed Consent and Release of Medical Information forms
- "Degenerative mitral valve disease refers to a spectrum of conditions in which morphologic changes in the connective tissues of the mitral valve cause structural lesions . . ., such as chordal elongation, chordal rupture, leaflet tissue expansion, and annular dilation typically resulting in mitral regurgitation due to leaflet prolapse." This definition excludes rheumatic heart disease. (Anyanwu AC, Adams DH. (2007) Etiological classification of degenerative mitral valve disease: Barlow's disease and fibroelasticity deficiency. Semin Thorac Cardiovasc Surg; 19(2): 90-6).
Exclusion Criteria:
- Functional MR
- Evidence of sub-optimal fluid management (e.g., lack of diuretics, weight in excess of dry weight) in the opinion of the cardiology investigator
- Structural / organic TV disease
- Severe TV regurgitation as determined by preoperative transthoracic echocardiography (TTE)
- Implanted pacemaker or defibrillator, where the leads cross the TV from the right atrium into the right ventricle
- Concomitant cardiac surgery other than atrial fibrillation correction surgery (PVI, Maze, LAA closure), closure of PFO or ASD, or CABG
- Cardiogenic shock at the time of randomization
- STEMI requiring intervention within 7 days prior to randomization
- Evidence of cirrhosis or hepatic synthetic failure
- Severe, irreversible pulmonary hypertension in the judgment of the investigator
- Pregnancy at the time of randomization
- Therapy with an investigational intervention at the time of screening, or plan to enroll patient in additional investigational intervention study during participation in this trial
- Any concurrent disease with life expectancy < 2 years
- Unable or unwilling to provide informed consent
- Unable or unwilling to comply with study follow up in the opinion of the investigator
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02675244
Show 41 study locations
| Principal Investigator: | Annetine C. Gelijns, PhD | Icahn School of Medicine at Mount Sinai | |
| Study Chair: | Richard Weisel, MD | Toronto General Hospital |
| Responsible Party: | Annetine Gelijns, Professor, Icahn School of Medicine at Mount Sinai |
| ClinicalTrials.gov Identifier: | NCT02675244 |
| Other Study ID Numbers: |
GCO 08-1078-0010 2U01HL088942-07 ( U.S. NIH Grant/Contract ) |
| First Posted: | February 5, 2016 Key Record Dates |
| Last Update Posted: | November 9, 2022 |
| Last Verified: | November 2022 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Tricuspid Valve Regurgitation |
|
Tricuspid Valve Insufficiency Heart Valve Diseases Heart Diseases Cardiovascular Diseases |